 In this trial, approximately 50 patients will receive the study drug, RAD001 in combination with bevacizumab Avastinchemotherapy. RAD001 will be taken orally once daily and bevacizumab will be administered intravenously once every 14 days. In addition to study treatment, a few blood samples and a sample of the patients tumor from a previous surgery if available will be collected for research. 